anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
All subjects received treatment (stimulation-assisted) with the Veinplicity Device per the Instructions for Use. The subject underwent standard IV cannulation using a 20 gauge cannula into the available vein immediately after completion of device stimulation. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
Objective: World Trade Center (WTC) responders are susceptible to both cognitive and neuropsychiatric impairments, particularly chronic posttraumatic stress disorder. The present study examined self-reported behavioral impairments in a sample of 732 WTC responders, 199 of whom were determined to have high risk of WTC-related cortical atrophy by an artificial neural network. Results: We found that responders at increased risk of cortical atrophy showed behavioral impairment across five domains: motivation, mood, disinhibition, empathy, and psychosis (14.6% vs 3.9% in the low-risk group; P = 3.90 × 10-7). Factor analysis models revealed that responders at high risk of cortical atrophy tended to have deficits generalized across all aspects of behavioral impairment with focal dysfunction in sensory psychosis. We additionally describe how relationships are modulated by exposure severity and pharmacological treatments. Discussion: Our findings suggest a potential link between sensory deficits and the development of cortical atrophy in WTC responders and may indicate symptoms consistent with a clinical portrait of parietal dominant Alzheimer's disease or a related dementia (ADRD). Results underscore the importance of investigating neuropsychiatric symptomatology in clinical evaluations of possible ADRD.
A precursor, non-radioactive HPLC standards and method for the synthesis of no-carrier-added N-(4-[18F]fluorobutyl)-Ethacrynic amide which has been proved a suitable PET (position emission tomography) probe for tumor GST imaging. The preparation of the title compound starts from precursors with the chemical structures as in Figure 1, wherein R1 is a protective group for the amide functional group, R2 acts as a leaving group. R1 represents a carboxyl group, and R2 represents a p-tosyloxy, methane sulfonyloxy or trifluoromethane sulfonyloxy or bromine. For non-radioactive HPLC standards, R1 is a protective group for the amide functional group or non protective group, R2 is a fluorine. R1 represents a carboxyl group or hydrogen, and R2 represents a fluorine. The invention includes a method for the syntheses of precursors and standards with the chemical structures (1).
Neurodegenerative diseases are conditions where the brain cells break down, causing mental and/or physical impairment. Alzheimer's Disease is a neurodegenerative disorder that affects millions of individuals and causes irreversible memory loss and cognitive impairment. Amyotrophic lateral sclerosis is also and incurable disorder that causes patients irreversible paralysis, which results in death due to inability to breath and suffocation. These disease have been shown to be associated with abnormalities in an important scaffolding called microtubules, a cellular structure that help support the shape of the cells. This study will explore an experimental imaging test to see if it can be used to help doctors identify early microtubule changes. The test involves the injection of a radioactive compound that has been shown to go to cells and bind to microtubules. Special cameras called Positron Emission Tomography (PET)/CT cameras will be used to allow doctors to view where the radioactive compound goes in the body, as this is the first time this radiolabeled agent is being used in humans. In this study, doctors will give the new compound to up to five healthy volunteers to see where it goes in the body of people who presumable have normal microtubule function. Then doctors will give \[11C\]MPC6827 to up to 30 additional subjects (healthy controls and patients with Alzheimers Disease or ALS) to focus on imaging the brain for extended times. The research-imaging drug in this study is \[11C\]MPC6827. The radioactive drug in this study is experimental, meaning it is not approved by the FDA and can only be used in research studies.
PCT No. PCT/NZ95/00062 Sec. 371 Date Jan. 8, 1997 Sec. 102(e) Date Jan. 8, 1997 PCT Filed Jul. 12, 1995 PCT Pub. No. WO96/02269 PCT Pub. Date Feb. 1, 1996The use of amylin as an agent for stimulation of bone growth is provided together with methods of stimulating bone growth comprising subjecting bone to an effective amount of amylin or amylin agonists. Medicaments containing amylin or an amylin agonist are provided. The amylin or amylin agonist is preferably in the form in which the presence of TFA is minimized or totally removed. Preferably a salt with an inert anion is used. The method will be particularly useful in treating bone disorders where stimulation of bone growth is required. The treatment of osteoporosis, bone loss of malignancy, or endocrine disorders or arthritides or immobility and disuse and in fractures are examples of the many disorders which may be treated. Previous bone loss can be reversed, and bone density can be increased or maintained.
SCN2A encodes NaV1.2, an excitatory neuron voltage-gated sodium channel and a major monogenic cause of neurodevelopmental disorders, including developmental and epileptic encephalopathies (DEE) and autism. Clinical presentation and pharmocosensitivity vary with the nature of SCN2A variant dysfunction and can be divided into gain-of-function (GoF) cases with pre- or peri-natal seizures and loss-of-function (LoF) patients typically having infantile spasms after 6 months of age. We established and assessed patient induced pluripotent stem cell (iPSC) - derived neuronal models for two recurrent SCN2A DEE variants with GoF R1882Q and LoF R853Q associated with early- and late-onset DEE, respectively. Two male patient-derived iPSC isogenic pairs were differentiated using Neurogenin-2 overexpression yielding populations of cortical-like glutamatergic neurons. Functional properties were assessed using patch clamp and multielectrode array recordings and transcriptomic profiles obtained with total mRNA sequencing after 2-4 weeks in culture. At 3 weeks of differentiation, increased neuronal activity at cellular and network levels was observed for R1882Q iPSC-derived neurons. In contrast, R853Q neurons showed only subtle changes in excitability after 4 weeks and an overall reduced network activity after 7 weeks in vitro. Consistent with the reported efficacy in some GoF SCN2A patients, phenytoin (sodium channel blocker) reduced the excitability of neurons to the control levels in R1882Q neuronal cultures. Transcriptomic alterations in neurons were detected for each variant and convergent pathways suggested potential shared mechanisms underlying SCN2A DEE. In summary, patient iPSC-derived neuronal models of SCN2A GoF and LoF pathogenic variants causing DEE show specific functional and transcriptomic in vitro phenotypes.
The present invention relates to a bacterial liquid culture, a freeze dried powder and a composition of Lactobacillus sp. in hot spring water, and a method of producing the same. The Lactobacillus sp. is cultivated in a culture medium including hot spring water under specific conditions, so that a bacterial liquid culture and/or a freeze dried powder including Lactobacillus sp. can be obtained. The bacterial liquid culture and/or the freeze dried powder including Lactobacillus sp. can be further added to a composition and a externally cosmetic product, thereby promoting the balanced microbial flora on the skin surface, and achieving the effects of preventing skin allergy, skin infection and anti-inflammation.
Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
Subjects will receive 2 punch biopsy created wounds, one on each thigh, which will be addressed with primary closure with sutures or will be treated with Nuvagen collagen powder at time of wounding and daily thereafter. Suture(s) will be removed in 2 weeks. At week four, the wounded site will be biopsied again for tissue collection/evaluation, and treated with primary closure again. Suture(s) will be removed within to weeks. For those using collagen powder, the biopsy site will be biopsied again at week 4, and wound care will again be with NuvagenTM collagen powder until closure.
The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with ATXN2 whether ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Spinocerebellar ataxia type 1 (SCA2). Also provided are materials and methods for editing a ATXN2 gene in a cell by genome editing. The present disclosure also provides materials and methods for altering the contiguous genomic sequence of a ATXN2 gene in a cell. In addition, the present disclosure provides one or more gRNAs for editing a ATXN2 gene. Also provided are therapeutics comprising at least one or more gRNAs for editing a ATXN2 gene. In addition, the present disclosure provides therapeutics for treating patients with a ATXN2 related condition or disorder.
The present invention relates to isolated or recombinant nucleic acids (DNA, RNA) which encode a latheo protein. The nucleic acids of the present invention include nucleic acids encoding human latheo protein (SEQ ID NO. 1), fly latheo protein (SEQ ID NO. 3) and characteristic portions thereof. The invention also relates to isolated or recombinantly produced latheo protein. For example, the latheo protein can be human latheo protein (SEQ ID NO. 4), fly latheo protein (SEQ ID NO. 2) and functional portions thereof. Also encompassed by the present invention is an agent which interacts with latheo directly or indirectly, and inhibits or enhances latheo function. The present invention further relates to a method of detecting latheo protein in a sample (e.g., blood, cerebral spinal fluid) obtained from an individual (e.g., human). The present invention further relates to a method of modulating dopamine levels in a mammal, comprising administering to the mammal an agent which interacts with latheo.
INTRODUCTION: Orthodontic treatment using face mask protraction combined with an alternate rapid maxillary expansion and constriction/protraction face mask (Alt-RAMEC/PFM) protocol is effective in the early treatment of patients with class III malocclusion, but the stability of treatment outcomes represents a major concern. Previous studies have suggested that tonsillar hypertrophy can be a risk factor for class III malocclusion and tonsillectomy may prompt the normalisation of dentofacial growth. However, these studies had a low-to-moderate level of evidence. This study was designed to identify the impact of tonsillectomy before orthodontic treatment on the efficacy and stability of Alt-RAMEC/PFM protocols and the sleep quality and oral health in children with anterior crossbite and tonsillar hypertrophy.
METHODS AND ANALYSIS: This is a two-arm, parallel-group, superiority cluster randomised controlled trial, with four clinics randomly assigned to the surgery-first arm and the orthodontic-first arm in a 1:1 ratio. The Alt-RAMEC protocol involves alternate activation and deactivation of the expander's jet screw over 6 weeks to stimulate maxillary suture distraction. Patients will be instructed to wear the PFM for a minimum of 14 hours per day. The primary outcomes are changes in Wits appraisal and the degree of maxillary advancement from baseline to the end of orthodontic treatment. Lateral cephalometric radiographs, polysomnography, Obstructive Sleep Apnoea-18 questionnaire and Oral Health Impact Profile-14 questionnaire will be traced, collected and measured. We will recruit 96 patients intofor the study. To assess differences, repeated multilevel linear mixed modelling analyses will be used.
ETHICS AND DISSEMINATION: This study has been granted ethical approval by the Ethics Committee of the School & Hospital of Stomatology, Wuhan University (approval No. 2023-D10). Written informed consent will be obtained from the participants and their guardians. The results of the trial will be disseminated through academic conferences and journal publications.
TRIAL REGISTRATION NUMBER: ChiCTR2300078833.
Placebo was administered once a day (oad) as matching oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
The present invention relates to the fields of veterinary parasitology and -vaccinology; more specifically the invention relates to a composition comprising live Eimeria oocysts and a pharmaceutically acceptable carrier. The composition is characterised in that it comprises a TLR3 agonist. The composition can be used to prepare a vaccine for poultry against Coccidiosis. The vaccine can be applied for example as a coarse spray on day-old chicks. The TLR3 agonist in the vaccine allows for a reduction of the dose of Eimeria oocysts up to 4 fold, while obtaining the same level of protection against challenge as from a vaccine without the TLR3 agonist. Alternatively, when employing a conventional dose of Eimeria oocysts in the vaccine, the TLR3 agonist causes an earlier onset of immunity, resulting in a significant reduction of the intestinal lesion score upon challenge, already at 2 instead of at 3 weeks after vaccination.
No intervention. Subjects are measured by ultrasound under 5 different postures of the hand for forty minutes.
FIELD: medicine. SUBSTANCE: method involves intranasally administering timogen 4 times a day at a dose corresponding to the actual age during 10-14 days. The course is to be repeated in 3-6 months. The age dose is 20-25 mcg for children within their first year, 40-45 mg for 1 to 5 years old children, 60-100 mg per day for children older than 5 years. EFFECT: enhanced effectiveness of treatment; prolonged remission time period. 2 cl, 1 tbl
Prostate cancer is a heritable disease with ancestry-biased incidence and mortality. Polygenic risk scores (PRSs) offer promising advancements in predicting disease risk, including prostate cancer. While their accuracy continues to improve, research aimed at enhancing their effectiveness within African and Asian populations remains key for equitable use. Recent algorithmic developments for PRS derivation have resulted in improved pan-ancestral risk prediction for several diseases. In this study, we benchmark the predictive power of six widely used PRS derivation algorithms, including four of which adjust for ancestry, against prostate cancer cases and controls from the UK Biobank and All of Us cohorts. We find modest improvement in discriminatory ability when compared with a simple method that prioritizes variants, clumping, and published polygenic risk scores. Our findings underscore the importance of improving upon risk prediction algorithms and the sampling of diverse cohorts.
Open-label TCZ. Injections were to be performed q1w or q2w depending on the approved label per region (last injection was administered at Week 10 or Week 11, depending on the dose regimen).
OBJECTIVE: The Pavlik harness (PH) has been widely used as the standard treatment for infants with developmental dysplasia of the hip (DDH). When the initial application of the PH fails, alternative treatments, such as closed reduction, open reduction, and reapplication of the PH will be considered. Compared with other treatments, reapplication of the PH offers certain advantages, including simplicity and reduced physical, and psychological stress, on both infants and caregivers. This study aims to investigate the effectiveness of reapplying the PH in patients with DDH.
METHODS: This study included patients with DDH (complete dislocation) who were treated by reapplication of PH between 1988 and 2012. Patients who were able to follow-up for more than 5 years were included. We examined the reduction rate and several factors to identify indicators associated with successful reduction during reapplication, including age, sex, side of hip dislocation, and the presence of the Ortolani sign. At the final follow-up, hip development was assessed using the Severin classification, whereas avascular necrosis (AVN) was evaluated using the Kalamchi classification and the Salter criteria.
RESULTS: A total of 56 patients (48 females and 8 males) and 57 hips were included in this study. The mean age at first and second application of PH was 4.2 months old (range: 0.12 to 6.4), and 5.8 months old (3.0 to 11.4), respectively. The reduction rate was 49% (28 out of 57 hips). Among the successfully reduced hips, the AVN rate was 3.6% (1 out of 28 hips). The Severin classification revealed 27 hips in class I and 1 hip in class III. Statistical analysis indicated a significantly higher proportion of left hip involvement in the reduction group (85% vs 41%, χ 2 test, P < 0.001). Although not statistically significant, the rate of positive Ortolani sign tended to be higher in the reduction group (61% vs 38%, χ 2 test, P = 0.06).
CONCLUSION: The reapplication method demonstrated a 49% reduction rate and a low AVN rate of 3.6% in our study. It is worth considering for patients who fail the initial PH treatment, particularly in cases of left-side dislocation and a positive Ortolani sign during the initial application.
NEW MATERIAL:A compound shown by the formula I [R is group shown by the formula II(m is 1-10; A and B are H or linked to form single bond; when m is >=2, A and B may be combination of the above-mentioned two cases)]. EXAMPLE:Farnesylglyceryl ether. USE:Especially useful as a component for cosmetic. Having chemical stability, low irritation to the skin, having surface active properties, useful as an emulsifying agent, oil agent, wetting agent, viscosity builder, etc. PREPARATION:For example, a terpene alcohol shown by the formula ROH is reacted with an epihalohydrin to give a glycidyl ether shown by the formula III, which is reacted with a lower fatty acid anhydride shown by the formula IV(R3 is 1-5C hydrocarbon group) in the presence of a basic catalyst, to give a glycerol diester shown by the formula V. This compound is hydrolyzed in an aqueous solution of an alkali substance such as an alkali metal hydroxide, etc. under heating, to give a high-purity compound shown by the formula I by simple operations in high yield.
Participants in the intervention group will need to engage in a 30-minute walk on five days every week for a duration of 12 weeks. To assist them in monitoring their activity and complying with the intervention guidelines, participants will receive a complimentary fitness watch. Weekly step counts will be collected from participants, who will report their data through a researcher-provided online link. The watch will come with an accompanying app for participants to access their data, but the researchers will not have access to this app.
OBJECTIVE: To understand the potential behavioral and cognitive effects of mesial temporal resection for temporal lobe epilepsy (TLE) a method is required to characterize network-wide functional alterations caused by a discrete structural disconnection. The objective of this study was to investigate network-wide alterations in brain dynamics of patients with TLE before and after surgical resection of the seizure focus using average regional controllability (ARC), a measure of the ability of a node to influence network dynamics.
METHODS: Diffusion-weighted imaging (DWI) data were acquired in 27 patients with drug-resistant unilateral mesial TLE who underwent selective amygdalohippocampectomy. Imaging data were acquired before and after surgery and a presurgical and postsurgical structural connectome was generated from whole-brain tractography. Edge-wise strength, node strength, and node ARC were compared before and after surgery. Direct and indirect edge-wise strength changes were identified using patient-specific simulated resections. Direct edges were defined as primary edges disconnected by the resection zone itself. Indirect edges were secondary measured edge strength changes. Changes in node strength and ARC were then related to both direct and indirect edge changes.
RESULTS: We found nodes with significant postsurgical changes in both node strength and ARC surrounding the resection zone (paired t tests, p < .05, Bonferroni corrected). ARC identified additional postsurgical changes in nodes outside of the resection zone within the ipsilateral occipital lobe, which were associated with indirect edge-wise strength changes of the postsurgical network (Fisher's exact test, p < .001). These indirect edge-wise changes were facilitated through the "hub" nodes including the thalamus, putamen, insula, and precuneus.
SIGNIFICANCE: Discrete network disconnection from TLE resection results in widespread structural and functional changes not predicted by disconnection alone. These can be well characterized by dynamic controllability measures such as ARC and may be useful for investigating changes in brain function that may contribute to seizure recurrence and behavioral or cognitive changes after surgery.
The invention belongs to the technical field of microbial prevention and treatment, and particularly relates to a vibrio parahaemolyticus phage VP-HYP MCS-1 and bdellovibrio bacteriovorax sp.MCS-1 composition and application thereof in prevention and treatment of prawn pathogenic vibrio parahaemolyticus infection. The vibrio parahaemolyticus phage is vibrio parahaemolyticus phage VP-HYP MCS-1, which is preserved in China general microbiological culture Collection center with the preservation number of CGMCC No. 19693. The bdellovibrio parahaemolyticus is bdellovibrio parahaemolyticus Halobactevorax sp.MCS-1, which is preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No. 19694. The virulent phage VP-HYP MCS-1 obtained by separation has strong host specificity and has cracking and killing effects on vibrio parahaemolyticus; MCS-1, which has a wide host spectrum and has cracking and killing effects on various vibrios including vibrio parahaemolyticus; the vibrio parahaemolyticus phage and bdellovibrio bacteriovorus provided by the invention have good application prospects in prevention and control of prawn pathogenic vibrio parahaemolyticus infection.
The present invention relates to a teeth whitening composition comprising 0.1 wt. % to 6 wt. % hydrogen peroxide, based on the total weight of the composition, and a nanohydroxy apatite having an average diameter of 0.1 to 20 nm. The present invention further relates to a teeth whitening kit comprising two separated components, wherein the first component comprises 0.1 wt. % to 6 wt. % hydrogen peroxide, based on the total weight of the first component, and the second component comprises a nanohydroxy apatite having an average diameter of 0.1 to 20 nm. The present invention also relates to a process for preparing a teeth whitening composition and to a dispenser for the teeth whitening kit.